Skip to content Skip to footer
Disease of the Month – Systemic Lupus Erythematosus

Disease of the Month – Systemic Lupus Erythematosus

Shots:  Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues  In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved    For a…

Read more

Monoclonal Antibodies Top 20 2024

Top 20 Monoclonal Antibodies of 2024

Shots: Transforming care with advanced mechanisms of action, monoclonal antibody therapies hold a strong foothold in the healthcare market In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Keytruda with $25.01B revenue ranks first in our list followed by…

Read more

PharmaShots Magazine - September 2024 Edition

PharmaShots Magazine – September 2024 Edition

Previously in PharmaShots Magazine, we explored Companion Animals as a theme. For the September Edition, our theme is centered on livestock animals. Livestock farming remains one of the key sectors in agrarian economies like India, China, and Latin American countries. Livestock farming provides us with milk and meat enriched with essential nutritional compounds like protein. …

Read more

CXO Talks: Jonathan Usuka Chief Business Officer at Sapient, in a Stimulating Conversation with PharmaShots

Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies. By leveraging Sapient's real-world data asset, the…

Read more

Insights+ Key Biosimilars Events of August 2024

Insights+ Key Biosimilars Events of August 2024

Shots:      Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency       Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients       The major highlights were the US FDA’s approval of Sandoz’s Enzeevu for Treating Neovascular Age-Related…

Read more

Oncology Top 20 2024

Top 20 Oncology Companies of 2024

Shots: With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…

Read more

New Drug Designations - July 2024

New Drug Designations – July 2024

Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 16 small molecules, 5 biologics, 11 cell & gene therapies, 1 recombinant protein, 1 vaccine, 1 immunotherapy, 1 radiopharmaceutical, 1 antisense oligonucleotide, 3 RNA therapies 1 herbal medicine…

Read more

Viewpoints_Manojkumar Bupathy

Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers  Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma   The study reveals that four out of the ten patients received only…

Read more